American Society of Hirudotherapy

Medicinal Leech Therapy in Urology: A PRISMA-Compliant Systematic Review

Battin AO, Hobeika N, Zdilla MJ (2023) · African Journal of Urology · n=12

RCT evidence detailTrial reference
Sample size of this trial compared with other Microsurgical Replantation (Digit / Ear / Scalp) trialsArbel EJ 202446Battin AO 202312Hong Ha N 20254van Alphen NA 20142Akhoondinasab MR 20231Banihani OI 20141Mousa A 20221Mendenhall SD 20161Momeni A 20141Senchenkov A 20131
This trial (highlighted) by sample size alongside other indexed Microsurgical Replantation (Digit / Ear / Scalp) trials. Larger trials generally carry more statistical weight.

Study Profile

Design
PRISMA-compliant systematic review of 12 unique medicinal leech therapy cases in urological contexts (MEDLINE/PubMed)
Sample size (n)
12
Intervention
Medicinal leech therapy across 12 urological cases: 4 post-penile replantation, 2 post-scrotal hematoma, 2 post-neonatal bladder exstrophy repair, 1 refractory priapism, 3 penoscrotal edema in hormone refractory prostate carcinoma
Comparator
Within-cohort comparison across diverse urological indications
Primary endpoint
Clinical improvement and complications across urological leech therapy applications
Primary result
All 12 cases (100%) reported clinical improvement; venous congestion/hematoma cases noted decreased displaced blood volume; priapism case had decreased pain; penoscrotal edema cases had significant swelling reduction; no complications in 9 adult patients; 3 neonatal patients required blood products
Follow-up duration
Variable across included cases

Key Findings

  • First PRISMA-compliant urology-specific leech review
  • 100% reported clinical improvement across 12 cases
  • Diverse indications: replant, hematoma, exstrophy, priapism, edema
  • No complications in 9 adult patients
  • 3 neonatal cases required blood products (volume-related)

Limitations

  • Small case pool (n=12 unique cases)
  • Publication bias toward successful outcomes
  • Heterogeneous indications limit cross-comparison
  • No control groups available
  • PRISMA methodology applied to case-level evidence

Clinical Implications

Battin 2023 establishes leech therapy as a viable urologic adjunct across diverse indications with favorable safety profile in adults. For US clinicians under K040187, this PRISMA review extends device application to refractory priapism, penoscrotal edema, and post-bladder exstrophy congestion contexts beyond the traditional flap-salvage indication. The neonatal blood product requirement highlights age-specific considerations.

Related Trials

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.